{"name":"Angde Biotech Pharmaceutical Co., Ltd.","slug":"angde-biotech-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Alteplase for Injection","genericName":"Alteplase for Injection","slug":"alteplase-for-injection","indication":"Ischemic stroke","status":"phase_2"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Recombinant human tissue plasminogen activator","genericName":"Recombinant human tissue plasminogen activator","slug":"recombinant-human-tissue-plasminogen-activator","indication":"Acute ischemic stroke","status":"phase_3"}]}],"pipeline":[{"name":"Alteplase for Injection","genericName":"Alteplase for Injection","slug":"alteplase-for-injection","phase":"phase_2","mechanism":"Alteplase for Injection is a tissue plasminogen activator that works by dissolving blood clots.","indications":["Ischemic stroke","Acute ischemic stroke"],"catalyst":""},{"name":"Recombinant human tissue plasminogen activator","genericName":"Recombinant human tissue plasminogen activator","slug":"recombinant-human-tissue-plasminogen-activator","phase":"phase_3","mechanism":"Recombinant human tissue plasminogen activator (rtPA) converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow.","indications":["Acute ischemic stroke","Acute myocardial infarction","Pulmonary embolism"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOZDZmTXRhTXZsSXFSVG85ZWNxMGcwaEt1STVwdGxhS0hZX2h0T3hteGM5STh0eHR2cjhTNFVLMFo4V1hKNE9FZzJWbFp6ck5jRG9QM0NHeW0xakF2ZXhQX056eWxCN3E0X1V1d2hhRm5Rc01iNENhQjRiMHF6V3lJdWNSa0JpRmJIcm40azRWSnF4OEFLbTZfS25FWUs?oc=5","date":"2026-03-30","type":"trial","source":"openPR.com","summary":"Ischemic Stroke Clinical Trial Pipeline Shows Potential with - openPR.com","headline":"Ischemic Stroke Clinical Trial Pipeline Shows Potential with","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}